Cerebral-vein thrombosis: Retrospective study of twenty seven cases;Thrombophlébite cérébrale: Étude rétrospective de vingt-sept cas

Revue de Medecine Interne

Volumn 23, Issue 12, 2002, Pages 973-982

  Rosenstingl, S ^a   Ruivard, M ^a   Melon, E ^a   Schaeffer, A ^a   Gouault Heilmann, M ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Cerebral vein thrombosis; Factor V Leiden; G20210A Prothrombin gene mutation; Haemostasis; Thrombophilia

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN VEIN; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DISEASE PREDISPOSITION; FAMILY HISTORY; FEMALE; GENE MUTATION; HEMOSTASIS; HOSPITAL; HUMAN; HYPERHOMOCYSTEINEMIA; LABORATORY; MALE; PATIENT REFERRAL; PREVALENCE; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INFANT; INTRACRANIAL THROMBOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 12244258200     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00685-9     Document Type: Article

References (47)

1. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992;10:87-111.
2. Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Juttler E, et al. Prothrombin gene G20210. A transition is a risk factor for cerebral venous thrombosis. Stroke 1998;29:1765-9.
3. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-30.
4. Dalhback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
5. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
6. Svenson PJ, Dalhback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-21.
7. Bertina MR, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
8. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343:1536-68.
9. Zoller, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
10. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
11. Poort RS, Rosendaal FR, Reistsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
12. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagul Fibrinolysis 1995;6:245-7.
13. Chu RC, Hall CA. The total serum homocysteine as an indicator of vitamin B12 and folate status. Am J Clin Pathol 1988;90:446-9.
14. Einhaupl KM, Villringer A, Meister W, Mehraein S, Gardner C, Pellkofer M, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597-600.
15. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis. A review of 38 cases. Stroke 1985;16:199-213.
16. Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol 1997;34:171-87.
17. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-44.
18. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-82.
19. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-82.
20. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
21. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997;78:315-26.
22. Rosing J, Tans G, Nicolaes GAF, Thomassen MCLGD, van Oerle R, van der Ploeg PMEN, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997;97:233-8.
23. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, osendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
24. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
25. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombingene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
26. Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci MP. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost 1996;76:475-80.
27. de Bruijn SFTM, Stam J, Koopman MMW, Vandenbroucke JP, for the Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Br Med J 1998(316):589-92.
28. Daif A, Awada A, Al-Rajeh S, Abduljabbar M, Rahman AL, Tahan A, Obeid T. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995;26:1193-5.
29. Najim AL, Al-Din AS, Mubaidin A, Wriekat AL, Alqam M. Risk factors of aseptic intracranial venous occlusive disease. Acta Neurol Scand 1994;90:412-6.
30. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001;85:430-4.
31. Rougemont D, Bousser MG, Wechsler B, Bletry O, Castaigne P, Godeau P. Manifestations neurologiques de la maladie de Behcet. Rev Neurol 1982;138:493-505.
32. Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Bletry O, et al. Cerebral venous thrombosis in Behçet's disease: Clinical study and long-term follow-up of 25 cases. Neurology 1992;42:614-8.
33. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996;7:1731-3.
34. Siegert CEH, Smelt AHM. Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis. Stroke 1997;28:1291-2.
35. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
36. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996;27:1721-3.
37. Rosendaal FR, Koster T, Vandenbroucke JP, Reistma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
38. Ridker PM, Hennekens CH, Lindpaintner K, Stampeer MJ, Eisenberg PR, Milelitch JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
39. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-7.
40. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene Mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996;75:393-4.
41. Bloem BR, van Putten MJAM, Meer FJM v d, van Hilten JJ, Bertina RM. Superior sagittal sinus thrombosis in a patient heterozygous for the novel 20210 A allele of the prothrombin gene. Thromb Haemost 1998;79:235.
42. Biousse V, Conard J, Brouzes C, Horellou MH, Ameri A, Bousser MG. Frequency of the 20210 G.A mutation in the 3′-untranslated region of the prothrombin gene in 35 cases of cerebral venous thrombosis. Stroke 1998;29:1398-400.
43. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080-3.
44. Fermo I, Vigano' D'Angelo S, Paroni R, Mazolla G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
45. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reistma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
46. Quéré I, Chassé JF, Dupuy E, Bellet E, Molho-Sabatier P, Tobelem G, et al. Homocystéine, 5,10-méthyl̀netetrahydrofolate réductase et thrombose veineuse profonde. Enquête auprès de 120 patients de médecine interne. Rev Méd Interne 1998;19:29-33.
47. Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996;27:243-6.